Carisma Therapeutics Stock Price Patterns
| CARM Stock | 0.04 0.01 13.04% |
Momentum 40
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.12) | EPS Estimate Current Year (0.69) | EPS Estimate Next Year (0.52) | Wall Street Target Price 1 | Quarterly Revenue Growth 12.368 |
Using Carisma Therapeutics hype-based prediction, you can estimate the value of Carisma Therapeutics from the perspective of Carisma Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
Carisma Therapeutics Hype to Price Pattern
Investor biases related to Carisma Therapeutics' public news can be used to forecast risks associated with an investment in Carisma. The trend in average sentiment can be used to explain how an investor holding Carisma can time the market purely based on public headlines and social activities around Carisma Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Carisma Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Carisma Therapeutics.
The fear of missing out, i.e., FOMO, can cause potential investors in Carisma Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Carisma because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Carisma Therapeutics after-hype prediction price | USD 0.04 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Carisma Therapeutics Basic Forecasting Models to cross-verify your projections. Carisma Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Carisma Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Carisma Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Carisma Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Carisma Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Carisma Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Carisma Therapeutics' historical news coverage. Carisma Therapeutics' after-hype downside and upside margins for the prediction period are 0.00 and 10.49, respectively. We have considered Carisma Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Carisma Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Carisma Therapeutics is based on 3 months time horizon.
Carisma Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Carisma Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Carisma Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Carisma Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.07 | 10.45 | 0.00 | 0.00 | 5 Events / Month | 4 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.04 | 0.04 | 3.09 |
|
Carisma Therapeutics Hype Timeline
Carisma Therapeutics is currently traded for 0.04. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Carisma is projected to increase in value after the next headline, with the price projected to jump to 0.04 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 3.09%, whereas the daily expected return is currently at -0.07%. The volatility of related hype on Carisma Therapeutics is about 130625.0%, with the expected price after the next announcement by competition of 0.04. Carisma Therapeutics currently holds 2.48 M in liabilities. Given the investment horizon of 90 days the next projected press release will be in about 5 days. Check out Carisma Therapeutics Basic Forecasting Models to cross-verify your projections.Carisma Therapeutics Related Hype Analysis
Having access to credible news sources related to Carisma Therapeutics' direct competition is more important than ever and may enhance your ability to predict Carisma Therapeutics' future price movements. Getting to know how Carisma Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Carisma Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| JSPR | Jasper Therapeutics | 0.17 | 8 per month | 0.00 | (0.11) | 7.19 | (8.14) | 31.75 | |
| ONCO | Onconetix | (0.11) | 7 per month | 0.00 | (0.05) | 16.34 | (11.27) | 36.81 | |
| ENVB | Enveric Biosciences | 0.00 | 0 per month | 0.00 | (0.07) | 10.37 | (11.42) | 121.83 | |
| SPRC | Scisparc | (0.01) | 8 per month | 0.00 | (0.37) | 5.00 | (12.50) | 30.69 | |
| SLXN | Biomotion Sciences Ordinary | (0.04) | 5 per month | 0.00 | (0.11) | 15.09 | (9.15) | 37.24 | |
| SLRX | Salarius Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.19) | 16.00 | (16.92) | 61.05 | |
| REVB | Revelation Biosciences | 0.19 | 8 per month | 0.00 | (0.24) | 6.84 | (10.16) | 35.57 | |
| CDT | Conduit Pharmaceuticals | 0.00 | 0 per month | 0.00 | (0.14) | 12.43 | (13.57) | 40.12 | |
| INDP | Indaptus Therapeutics | 0.00 | 0 per month | 0.00 | (0.06) | 16.13 | (13.41) | 51.64 | |
| ASBP | Aspire BioPharma | (0.1) | 9 per month | 0.00 | (0.22) | 19.52 | (23.85) | 66.08 |
Carisma Therapeutics Additional Predictive Modules
Most predictive techniques to examine Carisma price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Carisma using various technical indicators. When you analyze Carisma charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Carisma Therapeutics Predictive Indicators
The successful prediction of Carisma Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Carisma Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Carisma Therapeutics based on analysis of Carisma Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Carisma Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Carisma Therapeutics's related companies. | 2025 | 2026 (projected) | Dividend Yield | 0.11 | 0.096 | Price To Sales Ratio | 1.02 | 0.97 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Carisma Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Biotechnology sector continue expanding? Could Carisma diversify its offerings? Factors like these will boost the valuation of Carisma Therapeutics. Projected growth potential of Carisma fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Carisma Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.19 | Revenue Per Share | Quarterly Revenue Growth 12.368 | Return On Assets | Return On Equity |
Understanding Carisma Therapeutics requires distinguishing between market price and book value, where the latter reflects Carisma's accounting equity. The concept of intrinsic value - what Carisma Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Carisma Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Carisma Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Carisma Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Carisma Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.